Biopharmaceutical company developing treatments for diabetes, cardiovascular diseases, and rare diseases.
Lexicon Pharmaceuticals, Inc. is a dynamic biopharmaceutical company dedicated to advancing the frontier of pharmaceutical innovation through discovery, development, and commercialization. At the heart of its pipeline are orally-delivered small molecule drug candidates designed to address critical medical needs. Among these is Sotagliflozin, a promising therapeutic that has completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes, showcasing potential benefits across diverse patient populations.
In addition to Sotagliflozin, Lexicon Pharmaceuticals is actively developing LX9211, currently in Phase II clinical trials. This drug candidate targets neuropathic pain, addressing a significant area of unmet medical need with the potential to offer relief and improved quality of life for patients suffering from chronic pain conditions.
Lexicon Pharmaceuticals operates through strategic collaborations and license agreements with industry leaders such as Bristol-Myers Squibb Company and Genentech, Inc. These partnerships bolster the company's capabilities in research, development, and commercialization, facilitating the translation of innovative scientific discoveries into transformative therapies.
Established in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals continues to drive forward with a commitment to scientific excellence and patient-centered innovation. With a robust portfolio of advanced drug candidates and a strategic vision for growth, the company remains poised to make significant contributions to the healthcare landscape, improving outcomes for patients worldwide.